Trial Profile
Clinical Study on the Safety and Efficacy of Anti-BCMA CAR T Cells With Relapsed and Refractory Multiple Myeloma
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti BCMA CAR T Cell Therapy - Allife Medical Science and Technology (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
- 27 Jun 2018 New trial record